Literature DB >> 19257851

Functional cystic fibrosis transmembrane conductance regulator expression in cystic fibrosis airway epithelial cells by AAV6.2-mediated segmental trans-splicing.

Yuhu Song1, Howard H Lou, Julie L Boyer, Maria P Limberis, Luk H Vandenberghe, Neil R Hackett, Philip L Leopold, James M Wilson, Ronald G Crystal.   

Abstract

Cystic fibrosis is characterized by deficiency of the cystic fibrosis transmembrane conductance regulator (CFTR), a Cl(-) transporter. The packaging constraints of adeno-associated viral (AAV) vectors preclude delivery of both an active promoter and CFTR cDNA to target cells. We hypothesized that segmental trans-splicing, in which two AAV vectors deliver the 5' and 3' halves of the CFTR cDNA, could mediate splicing of two pre-mRNAs into a full-length, functional CFTR mRNA. Using a segmental trans-splicing 5' donor-3' acceptor pair that split the CFTR cDNA between exons 14a and 14b, cotransfection of donor and acceptor plasmids into CFTR(-) cells resulted in full-length CFTR message and protein. Microinjection of plasmids into CFTR(-) cells produced cAMP-activated Cl(-) conductance. Vectors created with an engineered human serotype, AAV6.2, were used to deliver CFTR donor and acceptor constructs, resulting in full-length CFTR mRNA and protein as well as cAMP-activated Cl(-) conductance in CFTR(-) cells, including human CF airway epithelial IB3-1 cells. Thus, segmental trans-splicing can be used with AAV vectors to mediate expression of CFTR, a strategy potentially applicable to individuals with CF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19257851      PMCID: PMC2855253          DOI: 10.1089/hum.2008.173

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  61 in total

1.  A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation.

Authors:  D Duan; Y Yue; Z Yan; J F Engelhardt
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

2.  Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy.

Authors:  Z Yan; Y Zhang; D Duan; J F Engelhardt
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

3.  Gene therapy for cystic fibrosis using cationic liposome mediated gene transfer: a phase I trial of safety and efficacy in the nasal airway.

Authors:  E J Sorscher; J J Logan; R A Frizzell; R K Lyrene; Z Bebok; J Y Dong; M D Duvall; P L Felgner; S Matalon; L Walker
Journal:  Hum Gene Ther       Date:  1994-10       Impact factor: 5.695

4.  Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors.

Authors:  C L Halbert; J M Allen; A D Miller
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus.

Authors:  B G Harvey; P L Leopold; N R Hackett; T M Grasso; P M Williams; A L Tucker; R J Kaner; B Ferris; I Gonda; T D Sweeney; R Ramalingam; I Kovesdi; S Shak; R G Crystal
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

6.  Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus.

Authors:  J A Wagner; A H Messner; M L Moran; R Daifuku; K Kouyama; J K Desch; S Manley; A M Norbash; C K Conrad; S Friborg; T Reynolds; W B Guggino; R B Moss; B J Carter; J J Wine; T R Flotte; P Gardner
Journal:  Laryngoscope       Date:  1999-02       Impact factor: 3.325

7.  Green fluorescent protein-based halide indicators with improved chloride and iodide affinities.

Authors:  L J Galietta; P M Haggie; A S Verkman
Journal:  FEBS Lett       Date:  2001-06-22       Impact factor: 4.124

8.  Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus.

Authors:  D Duan; Y Yue; Z Yan; J Yang; J F Engelhardt
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

9.  Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer.

Authors:  J Zabner; M Seiler; R Walters; R M Kotin; W Fulgeras; B L Davidson; J A Chiorini
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

10.  Repair of CFTR mRNA by spliceosome-mediated RNA trans-splicing.

Authors:  S G Mansfield; J Kole; M Puttaraju; C C Yang; M A Garcia-Blanco; J A Cohn; L G Mitchell
Journal:  Gene Ther       Date:  2000-11       Impact factor: 5.250

View more
  23 in total

Review 1.  Cell and gene therapy for genetic diseases: inherited disorders affecting the lung and those mimicking sudden infant death syndrome.

Authors:  Allison M Keeler; Terence R Flotte
Journal:  Hum Gene Ther       Date:  2012-06       Impact factor: 5.695

Review 2.  The AAV vector toolkit: poised at the clinical crossroads.

Authors:  Aravind Asokan; David V Schaffer; R Jude Samulski
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

3.  Cystic fibrosis transmembrane conductance regulator with a shortened R domain rescues the intestinal phenotype of CFTR-/- mice.

Authors:  Lynda S Ostedgaard; David K Meyerholz; Daniel W Vermeer; Philip H Karp; Lindsey Schneider; Curt D Sigmund; Michael J Welsh
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-01       Impact factor: 11.205

4.  The design and optimization of RNA trans-splicing molecules for skin cancer therapy.

Authors:  Christina Gruber; Ulrich Koller; Eva M Murauer; Stefan Hainzl; Clemens Hüttner; Thomas Kocher; Andrew P South; Helmut Hintner; Johann W Bauer
Journal:  Mol Oncol       Date:  2013-08-19       Impact factor: 6.603

5.  Optimization of adeno-associated virus vector-mediated gene transfer to the respiratory tract.

Authors:  F Kurosaki; R Uchibori; N Mato; Y Sehara; Y Saga; M Urabe; H Mizukami; Y Sugiyama; A Kume
Journal:  Gene Ther       Date:  2017-03-27       Impact factor: 5.250

Review 6.  Adeno-Associated Virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments.

Authors:  William B Guggino; Liudmila Cebotaru
Journal:  Expert Opin Biol Ther       Date:  2017-07-06       Impact factor: 4.388

7.  In vivo gene transfer strategies to achieve partial correction of von Willebrand disease.

Authors:  Lan Wang; Jonathan B Rosenberg; Bishnu P De; Barbara Ferris; Rui Wang; Stefano Rivella; Stephen M Kaminsky; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2012-06-25       Impact factor: 5.695

8.  CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes.

Authors:  Benjamin Steines; David D Dickey; Jamie Bergen; Katherine Jda Excoffon; John R Weinstein; Xiaopeng Li; Ziying Yan; Mahmoud H Abou Alaiwa; Viral S Shah; Drake C Bouzek; Linda S Powers; Nicholas D Gansemer; Lynda S Ostedgaard; John F Engelhardt; David A Stoltz; Michael J Welsh; Patrick L Sinn; David V Schaffer; Joseph Zabner
Journal:  JCI Insight       Date:  2016-09-08

Review 9.  CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors.

Authors:  Dan Wang; Feng Zhang; Guangping Gao
Journal:  Cell       Date:  2020-04-02       Impact factor: 41.582

Review 10.  Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies.

Authors:  James L Kreindler
Journal:  Pharmacol Ther       Date:  2009-11-10       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.